Reverse engineering of BNIP3 identifies a mitochondrial protective peptide.
BNIP3 just delivered a surprise: researchers reverse engineered this protein to create a peptide that shields mitochondria from self-destruction. Meet B-017, a lab-designed peptide that blocks BNIP3’s fatal handshake with BCL-2 executioner proteins. The result? Mitochondria stay intact, even under cellular stress.
Nat Commun
by Hendgen-Cotta UB, Roth A, Beuck C et al.
“Reverse engineering of BNIP3 identifies a mitochondrial protective peptide. Hendgen-Cotta UB(#)(1), Roth A(2), Beuck C(3), Messiha D(2), Settelmeier S(2), Shah SB(2), Korste S(2), Bravo-Rodriguez K(4), Blueggel M(3), Cansiz F(5), Martins Nascentes Melo L(5), Roesler J(5), Meckelmann SW(6), Schmitz OJ(6), Kaschani F(7), Kaiser M(8), Esfeld S(2), El Bounkari O(9), Bernhagen J(9)(10)(11), Brameyer S(12), Jung K(12), Schmitt LI(13), Leo M(13), Hagenacker T(13), Totzeck M(2), Minor T(14), Ehrmann M(15), Tasdogan A(5), Bayer P(3), Rassaf T(#)(16). Author information: (1)Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ulrike.hendgen-cotta@uk-essen.de. (2)Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. (3)Center of Medical Biotechnology, Research Group Structural and Medicinal Biochemistry, Faculty of Biology, University of Duisburg-Essen, Essen, Germany. (4)Department of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, Dortmund, Germany. (5)Department of Dermatology, Medical Faculty, University of Duisburg-Essen & German Cancer Consortium (DKTK), Essen, Germany. (6)Applied Analytical Chemistry, University of Duisburg-Essen, Essen, Germany. (7)Center of Medical Biotechnology, Analytics Core Facility Essen, Faculty of Biology, University of Duisburg-Essen, Essen, Germany. (8)Center of Medical Biotechnology, Chemical Biology, Faculty of Biology, University of Duisburg-Essen, Essen, Germany. (9)Division of Vascular Biology, Institute for Stroke and Dementia Research (ISD), LMU Klinikum, Ludwig-Maximilians-University (LMU) Munich, Munich, Munich, Germany. (10)German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. (11)Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. (12)Faculty of Biology, Microbiology, Ludwig-Maximilians-University (LMU) Munich, Martinsried, Germany. (13)Department auf Neurology and Center for Translational Neuro and Behavioral Science, Medical Faculty, University Hospital Essen, Essen, Germany. (14)Surgical Research Department, Medical Faculty, University Hospital Essen, Essen, Germany. (15)Center of Medical Biotechnology, Department of Microbiology, Faculty of Biology, University of Duisburg-Essen, Essen, Germany. (16)Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. tienush.rassaf@uk-essen.de. (#)Contributed equally Recent advances in mitochondrial network dynamic and signalling highlight mitochondria as key therapeutic targets across diverse diseases. Yet, high drug development failure rates reflect an incomplete understanding of upstream molecular regulators of mitochondrial fate. Here, we address this gap by reverse engineering of the BH3-only protein BNIP3. Structural modelling and sequence-function analyses of its N-terminus identify a critical functional domain and amino acid hotspots that directly activate BCL-2 executioner proteins, triggering mitochondrial cell death. Leveraging these insights, we develop a BNIP3 antagonist peptide (B-017) that disrupts interactions between BNIP3 and BCL-2 executioner proteins, preserving mitochondrial integrity. B-017 demonstrates target specificity, a favourable safety profile, and robust suppression of cell death signalling in human cells. In clinically relevant animal models, it reduces tissue damage in the heart, brain, and liver. Together, these findings position B-017 as a promising therapeutic candidate targeting mitochondrial dysfunction. © 2026. The Author(s). Conflict of interest statement: Competing interests: U.B.H.-C. and T.R. are co-founders of Bimyo GmbH. B-017 is covered by patent families EP19173715, PCT/EP2020/062929, US63/276028, PCT/EP2022/080979, US18/413,753, US63/599,595, US18/413,733, PCT/EP2024/082670, with the authors listed as inventors: U.B.H.-C. and T.R. The authors declare no competing interests.”
Why does this matter? Mitochondria aren’t just the cell’s power plants—they’re also gatekeepers for cell survival. When mitochondrial integrity fails, tissues in the heart, brain, and liver go down with them. The usual “therapeutic” approaches fumble because we don’t fully grasp what triggers mitochondrial catastrophe in the first place.
Here’s what the team did:
Broke down the BNIP3 protein to find its critical “death” domain.
Used structural modeling to pinpoint amino acids that flip the switch on mitochondrial cell death.
Designed B-017, a peptide that interrupts BNIP3’s connection with BCL-2 executioners.
B-017 isn’t just a blunt tool. It’s highly target-specific and showed a clean safety profile in human cell lines. Even better, in animal models, B-017 slashed tissue damage across vital organs. That’s not just theory—it’s hard data that points toward real translational value.
Key takeaway: Reverse engineering peptides from proteins like BNIP3 can unlock new ways to keep mitochondria—and whole tissues—alive under stress. This isn’t just about one peptide. It’s a proof-of-concept for mining protein domains to design targeted, protective research peptides.
Want to dig deeper into the world of lab-designed peptides and their applications? Check out the peptide research index for more breakthroughs. For sourcing options, browse our vendor directory. The next big mitochondrial protector might already be in the pipeline.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.